Alpha‐Lipoic Acid, Auraptene, and Particularly Their Combination Prevent the Metastasis of U87 Human Glioblastoma Cells

Abstract

Background . The primary malignant brain tumor glioblastoma multiforme (GBM) is most commonly detected in individuals over 60 years old. The standard therapeutic approach for GBM is radiotherapy combined with temozolomide. Recently, herbal products, such as alpha‐lipoic acid (ALA) and auraptene (AUR), have shown promising anticancer effects on various cancer cells and animal models. However, it is not well understood how ALA, AUR, and their combination in GBM work to combat cancer. Thus, the purpose of this study was to investigate the antimetastatic effects of the ALA‐AUR combination on U87 human glioblastoma cells. Methods . The inhibitory effects of ALA, AUR, and the ALA/AUR combination on the migration and metastasis of U87 cells were evaluated using a wound healing test and gelatin zymography. The expression levels of matrix metalloproteinase MMP‐2 and MMP‐9 were assessed at the transcriptional and translational levels using quantitative real‐time polymerase chain reaction (qRT‐PCR) and western blotting, respectively. Results . Our findings revealed that combination therapy reduced cell migration and metastasis, which was indicated by the reduction in MMP‐2/‐9 expression both at mRNA and protein levels, as well as their enzymatic activity in U87 cells. Conclusion . This study demonstrated that the combination of ALA and AUR effectively inhibited the migration and metastasis of U87 cells. Thus, given their safety and favorable specifications, the combination of these drugs can be a promising candidate for GBM treatment as primary or adjuvant therapy.